SPOTLIGHT -
Mixed Study Results in GU Tumor Types Reported From 2015 ECC
OncLive Chairman, Mike Hennessy
Renal Cell Carcinoma Vaccine Fails to Improve Outcomes
The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.
In Kidney Cancer, Better Outcomes Demonstrated With Nephron-sparing Surgery
Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.
Tasquinimod Discontinuation in mCRPC Discussed at 2015 ECC
Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naïve metastatic castration-resistant prostate cancer.
One Clinic's Multidisciplinary Approach Optimizes the Use of Radium-223
With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
Dr Westin on Outcomes of the SOLAR Trial in RAS-Mutant Gynecological Malignances
